Our Research Our principal research focus is on Drug Delivery and Nanomedicine. It encompasses mechanistic understanding of biological and pathological phenomena at the cellular, sub-cellular and biomolecular levels, and utilizing this knowledge to create bioinspired therapeutic and diagnostic technologies to interrogate, support, or treat the various …

Dr. Sen Gupta is the Director and Principal Investigator of the Bioinspired Engineering for Advanced Therapies (BEAT) laboratory. Dr. Sen Gupta received his MS (in 2001) and PhD (in 2003) from The University of Akron, Ohio, with focus on polymeric biomaterials engineering.

Sen Gupta, Anirban Platelet-inspired Biomedical Technologies: From Synthetic Hemostats to Targeted Drug Delivery Systems University of Kentucky 2014

Dr. Anirban Sen Gupta’s Google Scholar profile: link Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles for targeted fibrinolytic therapy Journal of Thrombosis & Hemostasis

The Sen Gupta laboratory on Bio-inspired Engineering for Advanced Therapies (BEAT) was founded in 2007. To date, the laboratory has received funding from foundation grants, state grants and federal grant mechanisms.

The physiological and pathological areas we focus on are hemostasis, thrombosis, inflammation, immune response and cancer metastasis

Sen Gupta Lab receives US Army PRMRP Award Excited to report that our lab has received a contract award from US Army PRMRP program to optimize and evaluate a new nanomedicine system for intravenous targeted enzyme-triggered direct delivery of …

Oct 15, 2015 · Dr. Sen Gupta and the BEAT laboratory has been awarded a new 5 year NIH R01 research grant ($1.9 million), an NCAI innovation grant ($250K) and a CCTRP translational research grant ($125K) to advance research in the area of platelet-inspired technologies, especially Synthetic Platelets and Thrombus-targeted Drug Delivery system.

Positions available. Contact us at senguptalab @ case.edu and axs262 @ case.edu with your CV/resume and why you are interested in our lab.

Dysregulated hemostatic mechanisms often lead to hyperaggregation of activated platelets and overaction of coagulation events, ultimately leading to occlusive clot formation. Such occlusive clotting is a primary characteristic in many vascular disease conditions, leading to ischemia, unstable angina, myocardial infarction, stroke etc. Such conditions lead to significant tissue …